ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marchac, V.
Right arrow Articles by Bush, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marchac, V.
Right arrow Articles by Bush, A.
Eur Respir J 2004; 23:98-102
Copyright ©ERS Journals Ltd 2004


Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients

V. Marchac1, A. Equi2, C. Le Bihan-Benjamin3, M. Hodson4 and A. Bush3

1 Service de Pneumologie et d'Allergologie Pédiatrique, and 3 Dépt de Bio-statistiques et Informatique Médicale, Hopital Necker-Enfants Malades, Paris, France. 2 Dept of Respiratory Paediatrics, and 4 Dept of Cystic Fibrosis, Royal Brompton & Harefield NHS Trust, London, UK

CORRESPONDENCE: A. Bush, Dept of Paediatric Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK. Fax: 44 2073518763. E-mail: a.bush@rbh.nthames.nhs.uk

Keywords: aspergillus fumigatus, cystic fibrosis, Stenotrophomonas maltophilia

Received: January 19, 2003
Accepted September 4, 2003

The aims of this case-control study were to describe the characteristics of cystic fibrosis (CF) patients who isolated Stenotrophomonas maltophilia in sputum, to determine risk factors for acquisition, to assess persistence of the organism and clinical outcomes postacquisition.

Data were collected from 1991–1999. CF patients and controls (who had never isolated S. maltophilia) were matched for age (±1 yr), sex and forced expiratory volume in one second (±10%). Data were collected from the year prior and for 2 yrs postacquisition of S. maltophilia.

The prevalence of S. maltophilia increased from 3.3% to 15%. Factors associated with S. maltophilia acquisition were more than two courses of intravenous antibiotics, isolation of Aspergillus fumigatus in sputum and oral steroid use. The effect of A. fumigatus was independent of steroid use. Clinical status did not change postacquisition. The majority of patients cleared the organism from the sputum.

Long-term infection or an accelerated deterioration in lung function or nutrition is not likely post-Stenotrophomonas maltophilia acquisition in cystic fibrosis. This is the first documentation of an association between Aspergillus fumigatus isolation and Stenotrophomonas maltophilia acquisition in cystic fibrosis, independently of steroid therapy.




This article has been cited by other articles:


Home page
ChestHome page
R. Amin, A. Dupuis, S. D. Aaron, and F. Ratjen
The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Patients With Cystic Fibrosis
Chest, January 1, 2010; 137(1): 171 - 176.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M. E. Falagas, P.-E. Valkimadi, Y.-T. Huang, D. K. Matthaiou, and P.-R. Hsueh
Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review
J. Antimicrob. Chemother., November 1, 2008; 62(5): 889 - 894.
[Abstract] [Full Text] [PDF]


Home page
JRSMHome page
J S. Elborn
Identification and management of unusual pathogens in cystic fibrosis
J R Soc Med, July 1, 2008; 101(Supplement_1): 2 - 5.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the European Respiratory Society.